Oxford Biomedica plc is a pure-play contract development and manufacturing organization (CDMO) focused on the cell and gene therapy sector. Originally founded as a drug development spin-out from the University of Oxford, the company has transitioned to providing bioprocessing and process development services to third parties. Its core offering is built around its proprietary LentiVector platform, alongside capabilities in adeno-associated virus (AAV) and adenoviral vectors. The company supports clients across the drug development continuum, offering services that range from pre-clinical process development to commercial GMP (Good Manufacturing Practice) manufacturing. With a geographic footprint spanning the United Kingdom, France, and the United States, Oxford Biomedica serves a global client base that includes major pharmaceutical companies and specialized biotech firms.
